Compugen (CGEN) Stock
Clinical stage biotech firm using computational drug discovery. Here's the price, business snapshot, and what's worth knowing about Compugen in June 2026.
Compugen Ltd (CGEN) is a clinical-stage biotechnology company that applies computational discovery to identify therapeutic targets, biomarkers and novel drug candidates, with a focus on immuno-oncology and precision medicine. The company leverages in‑house predictive platforms to nominate targets and advance a pipeline that can be progressed internally or licensed to partners. With a market capitalisation around $164.62M, Compugen is a small‑cap, development‑stage firm — potential upside from clinical or partnership milestones is matched by execution, funding and regulatory risks. Investors should note the firm may rely on collaborations, milestone payments or equity financing to fund development. Financial results and pipeline progress can be volatile; therapeutic development is lengthy and uncertain. This summary is for educational purposes only and is not personal investment advice. Investors should carry out their own research and consider risk tolerance before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Compugen's stock with a target price of $5, indicating significant growth potential.
Financial Health
Compugen Ltd is performing well in revenue and profit margins, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CGEN
Synthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: 17 June 2025
Explore BasketAI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Computational Discovery Edge
Compugen’s predictive platforms help nominate novel targets and biomarkers, a potential differentiator — though platform validation and clinical proof remain essential.
Milestones Drive Moves
Clinical readouts, partnerships or licensing deals can materially affect value; investors should expect volatility and monitor news flow closely.
Partnering Opportunities
The company’s model includes partnering to commercialise assets, which can accelerate development but depends on negotiation outcomes and counterparty execution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
